

1<sup>st</sup> June 2012


Dr Corinne Scott  
Administrator  
MREC for Wales  
6<sup>th</sup> Floor, Churchill House  
17 Churchill Way  
Cardiff  
CF10 2TW

Dear Dr Scott

**Re 08/MRE09/29 AML 17: A Programme of Development for the Treatment of Younger Patients with Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome**

On behalf of the Chief Investigator Prof Alan Burnett, I am writing to inform you of a non-substantial amendment to the above study. There has recently been a change in the pharmacovigilance details that are listed in the trial management group and also a typographical error on section 20.5.3 where the dosage of Mylotarg should read 3mg/m<sup>2</sup>. Therefore we have amended the protocol with the updated information, and to save any confusion, have updated the version to 7.2 dated June 2012

Yours Sincerely



Alison Jenkins  
AML17 Trial Manager